Compare FBYD & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBYD | EMBC |
|---|---|---|
| Founded | 2021 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 821.0M | 755.0M |
| IPO Year | N/A | N/A |
| Metric | FBYD | EMBC |
|---|---|---|
| Price | $6.70 | $10.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $18.50 |
| AVG Volume (30 Days) | 122.8K | ★ 495.6K |
| Earning Date | 11-14-2025 | 02-05-2026 |
| Dividend Yield | N/A | ★ 5.59% |
| EPS Growth | N/A | ★ 20.90 |
| EPS | 0.01 | ★ 1.62 |
| Revenue | $9,673,000.00 | ★ $1,080,400,000.00 |
| Revenue This Year | N/A | $2.00 |
| Revenue Next Year | N/A | $0.27 |
| P/E Ratio | $1,627.16 | ★ $6.63 |
| Revenue Growth | ★ 28.46 | N/A |
| 52 Week Low | $3.62 | $9.20 |
| 52 Week High | $29.02 | $19.67 |
| Indicator | FBYD | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 33.42 | 25.27 |
| Support Level | $5.81 | $12.01 |
| Resistance Level | $7.59 | $12.51 |
| Average True Range (ATR) | 1.35 | 0.48 |
| MACD | -0.34 | -0.21 |
| Stochastic Oscillator | 15.89 | 1.86 |
Falcons Beyond Global Inc. is a Company that provides a full range of theme park design, master planning, and experiential technologies for customers in the entertainment and attraction industry through its Falcon's Creative Group reportable segment and develops and co-owns resort and theme park attractions through its Destinations Operations. The Company has four operating segments, Falcon's Creative Group, PDP, Falcon's Beyond Brands, and Destinations Operations, all of which are reportable segments. It earns the majority of the revenue from Falcon's Creative Group segment.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.